Clinical Trials at Tennessee Oncology

As of June 2026, 56 paid clinical trials are recruiting at Tennessee Oncology, located at Tennessee Oncology PLLC: PET-Nashville, 322 22nd Ave N Suite 140, Nashville, TN 37203, phone (615) 320-7387 in Nashville, Tennessee. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

56 clinical trials at Tennessee Oncology

·Clear filters·↓ Download CSV

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

for Advanced Solid Tumors

7 locations incl. Los Angeles

Sponsor: LigaChem Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05941507·Phase 1, Phase 2·Recruiting

Apply to this trial

IKS014 in Advanced Solid Tumors That Express HER2

for Breast Cancer

4 locations incl. Newport Beach

Sponsor: Iksuda Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT05872295·Phase 1·Recruiting

Apply to this trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

for Breast Cancer

8 locations incl. Columbia

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05748834·Phase 2·Recruiting

Apply to this trial

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Iberdomide

44 locations incl. Aurora

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05827016·Phase 3·Recruiting

Apply to this trial

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

for Relapsed/Refractory B-cell Malignancies

9 locations incl. Denver

Sponsor: Accutar Biotechnology Inc

Sex: All·Age: 18+

Code: NCT05780034·Phase 1·Recruiting

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting

Apply to this trial

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

for Relapsed/Refractory Multiple Myeloma

16 locations incl. Birmingham

Sponsor: Caribou Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05722418·Phase 1·Recruiting

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

41 locations incl. Tucson

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting

Apply to this trial

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

for Breast Cancer

17 locations incl. Greenbrae

Sponsor: Tolmar Inc.

Sex: All·Age: 18 - 51

Code: NCT05645536·Phase 3·Enrolling By Invitation

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of INCB123667 in Subjects With Advanced Solid Tumors

for Solid Tumors

Drug: INCB123667

19 locations incl. Duarte

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05238922·Phase 1·Recruiting

Apply to this trial

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

for HER2-positive Advanced Solid Tumor

Drug: DB-1303/BNT323

35 locations incl. Cerritos

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT05150691·Phase 1, Phase 2·Recruiting

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

24 locations incl. Tucson

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting

Apply to this trial

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

for Chronic Lymphocytic Leukemia (CLL)

16 locations incl. Duarte

Sponsor: Nurix Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT04830137·Phase 1·Recruiting

Apply to this trial

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

for Hematological Malignancies

Drug: Talquetamab

14 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT04634552·Phase 2·Recruiting

Apply to this trial

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

for Advanced Solid Tumor

15 locations incl. Los Angeles

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT04145622·Phase 1, Phase 2·Recruiting

Apply to this trial